We are live on
!
Find out more
HVC
Healthcare Value Capital Portfolio holdings
AUM
$50.7M
Turnover
28.57%
1-Year Est. Return
24.72%
This Fund
S&P 500
This Quarter
Est. Return
+3.16%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$32.9M
AUM Growth
-$17.1M
(-34%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-36.29%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
15
New
2
Increased
2
Reduced
–
Closed
4
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
+$570K |
| 2 |
Standard BioTools
LAB
|
+$274K |
| 3 |
Seelos Therapeutics, Inc. Common Stock
SEEL
|
+$200K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$8.93M |
| 2 |
Assertio
ASRT
|
+$4.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.88% |
| 2 | Miscellaneous | 15.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TYME
1
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $13.2M | 40.26% |
2,075,000
| – | – |
2017 Q3
1 quarter
|
|
2
Gilead Sciences
GILD
$194B
| $5.37M | 16.34% |
75,000
| – | – |
2016 Q3
5 quarters
|
|
|
3
CALL
Gilead Sciences
GILD
$194B
| $4.3M | 13.07% |
60,000
| – | – |
2016 Q3
5 quarters
|
|
|
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $3.12M | 9.49% |
1,000,000
+118,560
| +13% | +$570K |
2016 Q4
4 quarters
|
|
|
5
Standard BioTools
LAB
$247M
| $2.42M | 7.35% |
410,500
+50,000
| +14% | +$274K |
2017 Q1
3 quarters
|
|
6
Amarin Corp
AMRN
$239M
| $1.8M | 5.49% |
22,500
| – | – |
2016 Q3
5 quarters
|
|
7
GSK
GSK
$99.2B
| $1.77M | 5.39% |
40,000
| – | – |
2017 Q3
1 quarter
|
|
8
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
| $551K | 1.68% |
3,125
| – | – |
2017 Q2
2 quarters
|
|
|
9
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $184K | 0.56% |
+1
| New | +$200K |
2017 Q4
0 quarters
|
|
10
PUT
MannKind Corp
MNKD
$977M
| $116K | 0.35% |
+50,000
| New | +$171K |
2017 Q4
0 quarters
|
|
|
FCSC
11
CALL
DELISTED
Fibrocell Science Inc.
FCSC
| $6K | 0.02% |
2,000
| – | – |
2017 Q2
2 quarters
|
|
|
12
DELISTED
Assertio
ASRT
| – | – |
-11,667
| Closed | -$4.05M | – |
|
|
13
PUT
DELISTED
Assertio
ASRT
| – | – |
-7,000
| Closed | -$2.43M | – |
|
|
14
CALL
Standard BioTools
LAB
$247M
| – | – |
-100,000
| Closed | -$504K | – |
|
|
15
Pfizer
PFE
$169B
| – | – |
-263,500
| Closed | -$8.93M | – |
|
Similar funds
C
CC
FCOI
FCOI
BI
KC
SCIM
MCP
Healthcare Value Capital's Q4 2017 Portfolio in Review
As of Q4 2017, Healthcare Value Capital held 15 positions worth $32.9M, down 34% from $50M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Healthcare Value Capital withdrew a net $11.9M in Q4 2017, closing 4 positions. Its most notable exit was Pfizer, an estimated $8.93M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Miscellaneous.
Against the trend, Healthcare Value Capital opened a new position in Seelos Therapeutics, Inc. Common Stock worth $184K.
- Healthcare Value Capital's largest Q4 2017 buy was Seelos Therapeutics, Inc. Common Stock: 1 share worth $184K.
- Healthcare Value Capital added most to Novelion Therapeutics Inc. Common Shares in Q4 2017, an estimated $570K increase.
- Healthcare Value Capital fully exited Pfizer in Q4 2017, selling an estimated $8.93M.
- Healthcare Value Capital's ten largest holdings make up 100% of its $32.9M portfolio in Q4 2017.
- Healthcare Value Capital opened 2 new positions and closed 4 in Q4 2017.
- Healthcare Value Capital's portfolio value fell 34% quarter-over-quarter to $32.9M.
Based on Healthcare Value Capital's 13F filing for Q4 2017, filed 23 Jan 2018.